134Oradiant-4: Efficacy and safety of everolimus in advanced, nonfunctional neuroendocrine tumors (Net) of the lung or gastrointestinal (Gi) tract
Yao, J.C.; Singh, S.; Wolin, E.; Voi, M.; Pacaud, L.B.; Lincy, J.; Sachs, C.; Valle, J.W.; Van Cutsem, E.; Shimada, Y.; Oh, D.-Y.
Annals of Oncology 26(Suppl 9): ix 40.1-ix 40
2015
ISSN/ISBN: 0923-7534 DOI: 10.1093/annonc/mdv522.01
Accession: 067408578
PDF emailed within 0-6 h: $19.90
Related References
2016: Everolimus for Advanced, Progressive, Nonfunctional Neuroendocrine Tumors (NET) of the Gastrointestinal (GI) Tract: Efficacy and Safety From a RADIANT-4 Subgroup Analysis Clinical Advances in Hematology and Oncology: H&o 14(5 Suppl. 7): 11-13Yao, J.; Fazio, N.; Singh, S.; Buzzoni, R.; Carnaghi, C.; Wolin, E.; Tomasek, J.; Raderer, M.; Lahner, H.; Voi, M.; Pacaud, L.; Lincy, J.; Sachs, C.; Valle, J.; Delle Fave, G. 2015: 5Lba Everolimus in advanced nonfunctional neuroendocrine tumors (Net) of lung or gastrointestinal (Gi) origin: Efficacy and safety results from the placebo-controlled, double-blind, multicenter, Phase 3 Radiant-4 study European Journal of Cancer 51: S709-S710
Yao, J.; Fazio, N.; Buzzoni, R.; Delle Fave, G.; Tesselaar, M.; Wolin, E.; Van Cutsem, E.; Tomassetti, P.; Strosberg, J.; Voi, M.; Pacaud, L.; Ridolfi, A.; Singh, S.; Pavel, M.; Kulke, M. 2016: ORAL02.02: Efficacy and Safety of Everolimus in Advanced, Progressive, Nonfunctional Neuroendocrine Tumors (NET) of the Lung: RADIANT-4 Subgroup Analysis: Topic: Medical Oncology Journal of Thoracic Oncology 11(11s): S253
Yao, J.C.; Oh, D.-Y.; Qian, J.; Park, Y.S.; Herbst, F.; Ridolfi, A.; Izquierdo, M.; Ito, T.; Jia, L.; Komoto, I.; Sriuranpong, V.; Shimada, Y. 2019: Everolimus for the treatment of advanced gastrointestinal or lung nonfunctional neuroendocrine tumors in East Asian patients: a subgroup analysis of the RADIANT-4 study Oncotargets and Therapy 12: 1717-1728
Kamp, K.; Gumz, B.; Feelders, R.A.; Kwekkeboom, D.J.; Kaltsas, G.; Costa, F.P.; de Herder, W.W. 2013: Safety and efficacy of everolimus in gastrointestinal and pancreatic neuroendocrine tumors after (177)Lu-octreotate Endocrine-Related Cancer 20(6): 825-831
Lee, L.; Igarashi, H.; Hijioka, M.; Ueda, K.; Fujiyama, T.; Tachibana, Y.; Kawabe, K.; Ito, T. 2015: Sa2048 Efficacy and Safety of Everolimus As Long-Term Treatment in Japanese Patients With Advanced Pancreatic Neuroendocrine Tumors Gastroenterology 148(4): S-393
Koumarianou, A.; Pectasides, D.G.; Manousou, K.; Dionysopoulos, D.; Kaltsas, G.A.; Kolomodi, D.; Poulios, C.; Skondra, M.; Samantas, E.; Pentheroudakis, G.; Fountzilas, G. 2018: Evaluation of the efficacy and safety of everolimus as a first-line treatment in newly diagnosed patients with advanced gastroenteropancreatic neuroendocrine tumors Annals of Oncology: Official Journal of the European Society for Medical Oncology 29 Suppl. 8: Viii 475
Rose, D.B.; Nellesen, D.; Neary, M.P.; Cai, B. 2017: Budget impact of everolimus for the treatment of progressive, well-differentiated, non-functional neuroendocrine tumors of gastrointestinal or lung origin that are advanced or metastatic Journal of Medical Economics 20(4): 395-404
Yao, J.C.; Fazio, N.; Singh, S.; Buzzoni, R.; Carnaghi, C.; Wolin, E.; Tomasek, J.; Raderer, M.; Lahner, H.; Voi, M.; Pacaud, L.B.; Rouyrre, N.; Sachs, C.; Valle, J.W.; Fave, G.D.; Van Cutsem, E.; Tesselaar, M.; Shimada, Y.; Oh, D.-Y.; Strosberg, J.; Kulke, M.H.; Pavel, M.E. 2016: Everolimus for the treatment of advanced, non-functional neuroendocrine tumours of the lung or gastrointestinal tract (RADIANT-4): a randomised, placebo-controlled, phase 3 study Lancet 387(10022): 968-977
Singh, S.; Carnaghi, C.; Buzzoni, R.; Pommier, R.F.; Raderer, M.; Tomasek, J.; Lahner, H.; Valle, J.W.; Voi, M.; Bubuteishvili-Pacaud, L.; Lincy, J.; Wolin, E.; Okita, N.; Libutti, S.K.; Oh, D.-Y.; Kulke, M.; Strosberg, J.; Yao, J.C.; Pavel, M.E.; Fazio, N. 2018: Everolimus in Neuroendocrine Tumors of the Gastrointestinal Tract and Unknown Primary Neuroendocrinology 106(3): 211-220
Oberstein, P.E.; Saif, M.W. 2012: Safety and efficacy of everolimus in adult patients with neuroendocrine tumors Clinical Medicine Insights. Oncology 6: 41-51
Ge, W.; Zhou, D.; Zhu, L.; Song, W.; Wang, W. 2018: Efficacy and Safety of Everolimus plus Somatostatin Analogues in Patients with Neuroendocrine Tumors Journal of Cancer 9(24): 4783-4790
Chua, A.; Perrin, A.; Ricci, J.F.; Neary, M.P.; Thabane, M. 2018: Cost-effectiveness of everolimus for the treatment of advanced neuroendocrine tumours of gastrointestinal or lung origin in Canada Current Oncology 25(1): 32-40
Chua, A.; Perrin, A.; Ricci, J.F.; Neary, M.P.; Thabane, M. 2018: Erratum: Cost-effectiveness of everolimus for the treatment of advanced neuroendocrine tumours of gastrointestinal or lung origin in Canada Current Oncology 25(4): E354-E355
Vernieri, C.; Pusceddu, S.; Fucà, G.; Indelicato, P.; Centonze, G.; Castagnoli, L.; Ferrari, E.; Ajazi, A.; Pupa, S.; Casola, S.; Foiani, M.; Mazzaferro, V.; Pruneri, G.; Milione, M.; de Braud, F. 2019: Impact of systemic and tumor lipid metabolism on everolimus efficacy in advanced pancreatic neuroendocrine tumors (pNETs) International Journal of Cancer 144(7): 1704-1712
Yao, J.C.; Phan, A.T.; Chang, D.Z.; Wolff, R.A.; Hess, K.; Gupta, S.; Jacobs, C.; Mares, J.E.; Landgraf, A.N.; Rashid, A.; Meric-Bernstam, F. 2008: Efficacy of RAD001 (everolimus) and octreotide LAR in advanced low- to intermediate-grade neuroendocrine tumors: results of a phase Ii study Journal of Clinical Oncology: Official Journal of the American Society of Clinical Oncology 26(26): 4311-4318
Fazio, N.; Buzzoni, R.; Delle Fave, G.; Tesselaar, M.E.; Wolin, E.; Van Cutsem, E.; Tomassetti, P.; Strosberg, J.; Voi, M.; Bubuteishvili-Pacaud, L.; Ridolfi, A.; Herbst, F.; Tomasek, J.; Singh, S.; Pavel, M.; Kulke, M.H.; Valle, J.W.; Yao, J.C. 2018: Everolimus in advanced, progressive, well-differentiated, non-functional neuroendocrine tumors: RADIANT-4 lung subgroup analysis Cancer Science 109(1): 174-181
Anthony, L.; Bajetta, E.; Kocha, W.; Panneerselvam, A.; Saletan, S.; OʼDorisio, T. 2011: Efficacy and Safety of Everolimus Plus Octreotide LAR in Patients with Colorectal Neuroendocrine Tumors (NET): Subgroup Analysis of the Phase IIi RADIANT-2 Trial American Journal of Gastroenterology 106: S154-S155
Liu, C-Ting.; Chen, M-Huang.; Chen, J-Shi.; Chen, L-Tzong.; Shan, Y-Shen.; Lu, C-Hsien.; Su, Y-Li.; Ku, F-Chen.; Chou, W-Chi.; Chen, Y-Yang. 2016: The efficacy and safety of everolimus for the treatment of progressive gastroenteropancreatic neuroendocrine tumors: A multi-institution observational study in Taiwan Asia-Pacific Journal of Clinical Oncology 12(4): 396-402
Yao, J.C.; Strosberg, J.; Fazio, N.; Pavel, M.E.; Ruszniewski, P.; Bergsland, E.; Li, D.; Tafuto, S.; Raj, N.; Campana, D.; Hijioka, S.; Raderer, M.; Guimbaud, R.; Gajate, P.; Pusceddu, S.; Reising, A.; Degtyarev, E.; Mookerjee, B.; Aimone, P.; Singh, S. 2018: Activity & safety of spartalizumab (PDR001) in patients (pts) with advanced neuroendocrine tumors (NET) of pancreatic (Pan), gastrointestinal (GI), or thoracic (T) origin, & gastroenteropancreatic neuroendocrine carcinoma (GEP NEC) who have progressed on prior treatment (Tx) Annals of Oncology: Official Journal of the European Society for Medical Oncology 29 Suppl. 8: Viii 467-Viii 468